Virtual Library
Start Your Search
Gabriel Mak
Author of
-
+
Lunch & Poster Display session (ID 58)
- Event: ELCC 2019
- Type: Poster Display session
- Track:
- Presentations: 1
- Moderators:
- Coordinates: 4/11/2019, 12:30 - 13:00, Hall 1
-
+
67TiP - ADRIATIC: A phase III trial of durvalumab ± tremelimumab after concurrent chemoradiation for patients with limited stage small cell lung cancer (ID 237)
12:30 - 13:00 | Author(s): Gabriel Mak
- Abstract
Background
Limited stage small-cell lung cancer (LS-SCLC), which represents ∼30% of newly diagnosed SCLC, remains an area of high unmet medical need. Standard of care, which has not changed for several decades, consists of curative intent platinum-based chemotherapy concurrent with radiotherapy (cCRT) followed by prophylactic brain irradiation (PCI) and observation. Despite good response to cCRT, outcomes remain poor, with median progression-free survival (PFS) ∼15 months and overall survival (OS) ∼25 months. Durvalumab (D) is a selective, high-affinity, human IgG1 monoclonal antibody (mAb) that blocks programmed cell death ligand-1 binding to programmed cell death-1 and CD80. Tremelimumab (T) is a selective human IgG2 mAb against CTLA-4. D demonstrated a PFS and OS advantage over placebo in locally advanced NSCLC following cCRT. D and D + T demonstrated a tolerable safety profile and antitumour activity in pretreated extensive stage SCLC. The ADRIATIC trial (NCT03703297) will assess if treatment with D ± T is beneficial vs placebo in patients (pts) with LS-SCLC who have not progressed following cCRT.
a9ded1e5ce5d75814730bb4caaf49419 Trial design
ADRIATIC is a Phase 3, randomised, double-blind, multicentre, placebo-controlled international trial. Pts (N∼600) will be randomised 1:1:1 to receive D + placebo T, D + T, or dual placebo, stratified by Stage (I/II vs III) and receipt of PCI at the investigator’s discretion (yes vs no). Eligible pts must have confirmed inoperable Stage I–III LS-SCLC; WHO/ECOG PS 0/1; and completed 4 cycles of cCRT with a response of stable disease or better within 1–42 days prior to randomisation. Pts will receive the assigned treatment until clinical, RECIST v1.1-defined progressive disease, intolerable toxicity or for a maximum of 24 months, whichever comes first. Primary objectives are PFS and OS for D ± T vs placebo. Key secondary endpoints include health-related quality of life, and safety and tolerability. Recruitment is ongoing
d9b324a48b043b3d87bc9b3fe620f260 Clinical trial identificationArm Dose Initial regimen (first 4 cycles) Continuation regimen (up to 24 months) D + placebo T D = 1500 mg (intravenous [i.v.]) D + placebo T q4w D q4w alone after the final dose of D + placebo T D + T combination D = 1500 mg (i.v.)T = 75 mg (i.v.) D + T q4w D q4w alone after the final dose of D + T Placebo D + placebo T i.v. saline Placebo D + placebo T q4w Placebo D q4w
NCT03703297.
7a6a3ffa2dadc03a6151ee2c4d6fa383 Editorial acknowledgement
Medical writing support, which was in accordance with Good Publication Practice (GPP3) guidelines, was provided by Craig Turner, MSc, of Cirrus Communications, an Ashfield company (Macclesfield, UK), and was funded by AstraZeneca.
934ce5ff971f1ab29e840a35e3ca96e9 Legal entity responsible for the study
AstraZeneca PLC.
213f68309caaa4ccc14d5f99789640ad Funding
AstraZeneca.
682889d0a1d3b50267a69346a750433d Disclosure
S. Senan: Departmental research grant: AstraZeneca, Varian Medical Systems, ViewRay Inc.; Advisory boards: AstraZeneca, MSD, Eli Lilly, Celgene. N. Shire: Employment, stock: AstraZeneca, outside the submitted work. G. Mak W. Yao, H. Jiang: Employment, stock: AstraZeneca, outside the conduct of the study.
cffcb1a185b2d7d5c44e9dc785b6bb25
